Parents need greater support to guide safe online behaviour for children, report says
Parents need greater support to guide safe online behaviour as digital technologies reshape childhood, a report has concluded.
The Economic and Social Research Institute (Esri) research, commissioned by BlockW, highlights the complexities and risks associated with children's digital technology use.
Advertisement
It found that school-aged children and adolescents are spending more time online than ever before.
An international literature review, conducted by the Esri's Behavioural Research Unit, explores the impact of digital technology on children's wellbeing, the challenges faced by parents, and potential public health interventions.
The review reveals that while digital technologies offer numerous benefits, such as access to information, educational tools, and social connection, they also pose risks to the wellbeing of children and adolescents.
The researchers have called for the need for effective policies to protect children online, guided by a thorough understanding of when and how digital technologies cause harm.
Advertisement
The report found that digital technologies can offer benefits for children, including opportunities for social connection, learning, creativity, exploration, seeking support, and play.
However, some types of social media and gaming can harm wellbeing.
These effects are shaped by socioeconomic factors, the child's gender, developmental stage, and cultural and social context.
Parents are often considered the first, last, and strongest line of defence for their children's online safety, the report stated.
Advertisement
Yet, they face digital risks themselves, including device overuse.
The report said that effective parenting strategies involve active mediation, setting clear rules and boundaries, and modelling appropriate behaviour.
Over-reliance on technical controls can be counterproductive and harm the parent-child relationship, it added.
Ensuring children's online safety requires coordinated efforts from parents, schools, digital technology companies, and governments.
Advertisement
Policymakers could consider regulations for robust age verification and standardised content reporting mechanisms to better protect children from harmful digital environments and promote safer online spaces.
Dr Celine Fox, lead author on the report, said: 'Our review suggests there is an urgent need for better research to more accurately measure the impact of digital technologies on children's wellbeing and what can be done to mitigate the risks.
'Digital technologies evolve rapidly, so the true extent of the challenges faced by parents and children in the digital era is likely not yet fully understood.'
Ireland
Children as young as eight exposed to 'disturbing...
Read More
Professor Joyce O'Connor, chairwoman and co-founder of BlockW, said: 'As digital technologies reshape childhood, parents need greater support to guide safe online behaviour.
Advertisement
'Online safety needs to be a shared responsibility across families, schools, platforms, and policymakers and not a burden parents carry alone.
'This study is a vital first step – further research is essential to inform and develop how best to reach parents with effective, evidence-informed solutions.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 hours ago
- The Independent
Weight loss jab could be used to treat migraines
Weight loss jabs could cut the number of migraines sufferers experience by half, research suggests. The drugs, similar to Ozempic and Wegovy, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Researchers have discovered, GLP-1 drug liraglutide, commonly used to treat diabetes, has the potential to significantly reduce migraine frequency. Migraines affect approximately 6 million people in the UK, according to the NHS. Attacks can last for three days causing pain, nausea, vomiting, dizziness and sensitivity to light, sound and smells. Researchers at the Headache Centre of the University of Naples gave 26 adults with obesity and chronic migraines the drug liraglutide. The study presented at the European Academy of Neurology (EAN) Congress 2025, found those who had the drug reported an average of 11 fewer headache days per month. Participants also experienced meaningful improvements in quality of life, work, study, and social functioning within just two weeks of taking the drug. 'Most patients felt better within the first two weeks and reported quality of life improved significantly', said lead researcher Dr Simone Braca. 'The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant.' Growing evidence has linked subtle increases in intracranial pressure to migraine attacks. It's caused by a rise in the pressure of cerebrospinal fluid – which surrounds the brain and spinal cord. This increase in pressure can happen because of a severe head injury, stroke, a brain tumour or high blood pressure. But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH). Patients in the study were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out IIH. Dr Braca and colleagues believe GLP-1 drugs may reduce the release of CGRP (calcitonin gene-related peptide), a key molecule behind migraines. 'We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide', Dr Braca said. 'That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.' Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology, study authors said.
The Independent
3 hours ago
- The Independent
Popular children's cough medicine recalled over potentially deadly bacterial infection risk
A popular cough medicine for children has been recalled over a risk of bacterial infection that can be deadly. Little Remedies Honey Cough Syrup was recalled Tuesday over the 'presence' of Bacillus cereus, a type of bacteria that can cause two types of foodborne illnesses, and because of 'loss of shelf-stability,' according to a notice from the medicine makers, Medtech Products Inc. The recall describes the symptoms associated with both foodborne illnesses. One can cause nausea, vomiting and stomach cramps starting one to six hours after consuming contaminated food. The second illness can cause stomach cramps and diarrhea starting 8 to 16 hours after exposure. 'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death,' the recall notice warned. No serious adverse effects have been reported as of the date of the recall. The recalled cough syrup was sold by retailers throughout the country and online from December 14, 2022, to June 4, 2025. Consumers with the recalled medicine are advised to stop using it immediately and contact their doctor if they experience any symptoms that may be related to the product. The company is also offering a refund of the product.
The Sun
5 hours ago
- The Sun
Sex drug Viagra has surprising new health benefit and could help 3 million ageing Brits, say scientists
SEX aid pill Viagra helps stiffen your skeleton, a study suggests. The little blue tablet was found to increase production of vital bone cells — so could one day prevent back pain and fractures in old age. Researchers found sildenafil, which is branded as Viagra, helped human stem cells transform into osteoblasts, the bone-building cells. These are vital as the human skeleton regenerates and is completely replaced roughly once every ten years. As we age, we lose more bone than we build, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. The Peking University team's follow-up tests on mice also suggested sildenafil would prevent bone loss. Dr Menglong Hu and Dr Likun Wu said: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' More than three million Britons suffer osteoporosis. Other treatments exist but the researchers said it would be handy to have more cheap and readily available drugs. They said: 'Any new drug must be evaluated. This is time-consuming, expensive and risky. But sildenafil is approved and safe.' Viagra was invented as a heart drug in the 1980s before it was found to help with erectile dysfunction. Studies have since suggested it might also reduce dementia risk. Why You Should Think Twice Before Popping Viagra Just For Fun (1)
